Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383677 | 1.00 | CDK1 (0.70) | CDK1TDP1MAPK1NAAAKCNMA1 | |
| SCHEMBL14567055 | 1.00 | CDK1 (0.70) | CDK1TDP1MAPK1NAAAKCNMA1 | |
| SCHEMBL2330852 | 0.99 | CDK1 (0.68) | CDK1TDP1MAPK1NAAAKCNMA1 | |
| SCHEMBL5497301 | 0.99 | CDK1 (0.68) | CDK1TDP1MAPK1NAAAKCNMA1 | |
| SCHEMBL4622847 | 0.99 | CDK1 (0.72) | CDK1TDP1MAPK1NAAAKCNMA1 | |
| Trimethylammonium SCHEMBL29036046 | 0.95 | CDK1 (0.64) | CDK1TDP1MAPK1NAAAKCNMA1 | |
| Alcohol SCHEMBL1277192 | 0.95 | CDK1 (0.67) | CDK1TDP1MAPK1NAAAKCNMA1 | |
| SCHEMBL2330956 | 0.94 | CDK1 (0.74) | CDK1TDP1MAPK1NAAAKCNMA1 | |
| Alcohol SCHEMBL2337118 | 0.94 | CDK1 (0.66) | CDK1TDP1MAPK1NAAAKCNMA1 | |
| Pyrrole SCHEMBL30481042 | 0.93 | CDK1 (0.61) | CDK1TDP1MAPK1NAAAKCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 930 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069697-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260000617-A1 | ORAL BIOLOGIC MACROMOLECULE DELIVERY SYSTEM | NUTRITION & BIOSCIENCES USA 1 LLC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4642440-A1 | COMPOSITIONS AND METHODS TO INCREASE THE SYSTEMIC BIOAVAILABILITY OF A POLYPEPTIDE THERAPEUTIC AGENT UNDERGOING ORAL ADMINISTRATION | ALGIPHARMA AS (NO) | 2025-11-05 | — | — | EP | claimed |
| EP-4611730-A1 | ORAL BIOLOGIC MACROMOLECULE DELIVERY SYSTEM | Nutrition & Biosciences USA 1, LLC (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025097068-A1 | ORAL DOSAGE FORM WITH IONICALLY CHARGEABLE HYDROGEL FOR DELIVERY OF ACTIVE AGENT AND PERMEATION ENHANCER | ENTREGA INC. (US) | 2025-05-08 | — | — | WO | claimed |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | CIVI BIOPHARMA, INC. (US) | 2025-05-06 | — | — | US | claimed |
| US-20250009666-A1 | RAPIDLY DISSOLVING SALT TABLET COMPOSITIONS AND METHODS | TARRATS LUISAM (US) | 2025-01-09 | — | — | US | claimed |
| US-20240261411-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | SYNTIS BIO, INC. | 2024-08-08 | — | — | US | claimed |
| EP-1420827-A1 | 5-CNAC AS ORAL DELIVERY AGENT FOR PARATHYROID HORMONE FRAGMENTS | Novartis AG (CH) | 2004-05-26 | — | — | EP | claimed |
| WO-2004012772-A1 | ORAL ADMINISTRATION OF CALCITONIN | NOVARTIS AG (CH) | 2004-02-12 | — | — | WO | claimed |
| WO-2004006907-A1 | MODIFIED AMINO ACID FOR THE INHIBITION OF PLATELET AGGREGATION | NOVARTIS AG (CH) | 2004-01-22 | — | — | WO | claimed |
| US-20030216593-A1 | Method of preparing salicylamides | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2003-11-20 | — | — | US | claimed |
| WO-2003015822-A1 | 5-CNAC AS ORAL DELIVERY AGENT FOR PARATHYROID HORMONE FRAGMENTS | NOVARTIS AG (CH) | 2003-02-27 | — | — | WO | claimed |
| EP-1175390-A4 | DISODIUM SALTS, MONOHYDRATES, AND ETHANOL SOLVATES | EMISPHERE TECH INC (US) | 2002-09-04 | — | — | EP | claimed |
| US-20020065255-A1 | Disodium salts, monohydrates, and ethanol solvates for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2002-05-30 | — | — | US | claimed |
| EP-1175390-A1 | DISODIUM SALTS, MONOHYDRATES, AND ETHANOL SOLVATES | Emisphere Technologies, Inc. (US) | 2002-01-30 | — | — | EP | claimed |
| WO-2001092206-A1 | METHOD OF PREPARING SALICYLAMIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2000059863-A1 | DISODIUM SALTS, MONOHYDRATES, AND ETHANOL SOLVATES | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065255-A1 | Disodium salts, monohydrates, and ethanol solvates for delivering active agents | ADH1C, CLIC1, SLC9A1 | CDK1 4120/4885TDP1 4270/4885MAPK1 2874/4885 |
| US-20240261411-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | FABP2, SLC10A2, FABP6 | CDK1 2604/4885TDP1 4613/4885MAPK1 3260/4885 |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | CDK1 3743/4885TDP1 2676/4885MAPK1 2860/4885 |
| US-20030216593-A1 | Method of preparing salicylamides | SCLY, ADSL, SIK3 | CDK1 880/4885TDP1 3446/4885MAPK1 2978/4885 |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | PCSK9, SCD5, PCSK7 | CDK1 2420/4885TDP1 1921/4885MAPK1 4221/4885 |
| US-20260000617-A1 | ORAL BIOLOGIC MACROMOLECULE DELIVERY SYSTEM | SI, FABP2, VIP | CDK1 3764/4885TDP1 4084/4885MAPK1 2339/4885 |
| US-20260069697-A1 | METHOD OF TREATING CANCER | PBK, GZMB, KLRK1 | CDK1 3686/4885TDP1 3626/4885MAPK1 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.